Leprid

Quick links to important sections

Leprid

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Leprid

Property Description
Active ingredient Leuprorelin acetate
Form Injection (Powder for suspension or Solution)
Pharmacological class Gonadotropin-Releasing Hormone (GnRH) Agonist
General Purpose Induction of hormonal deprivation
Origin Synthetic nonapeptide analog

Defining Leprid: Substance, Class, and Composition

Leprid is a highly specialized, potent pharmaceutical preparation primarily identified by its active component, Leuprorelin acetate, which acts as a hormonal modulator. It is formally classified as a Gonadotropin-Releasing Hormone (GnRH) agonist. This classification places it among hormone therapy agents that are clinically recognized for their ability to regulate the body's endocrine signaling system.

The active substance, Leuprorelin (also known as Leuprolide), is a synthetic nonapeptide analog—a chemically engineered version of the naturally occurring GnRH. This synthetic structure gives it superior stability and greater potency than the natural hormone. Leprid is a single-entity product, meaning its therapeutic effect derives solely from this one active chemical substance, and it is supplied exclusively for parenteral administration as an injection.

Form and Type: Why is Leprid an Injection?

Leprid is prepared for use only as an injection because the peptide structure of Leuprorelin is rapidly broken down and rendered ineffective if taken orally in the digestive system. The medication is commonly supplied in a long-acting depot formulation, which is a specialized drug type.

This depot technology, often involving polymeric microspheres, allows for the controlled, continuous release of the active substance over extended periods. This delivery system is crucial for maintaining the consistent, uninterrupted presence of the drug required to achieve its primary pharmacological goal.

General Purpose: Achieving Hormonal Deprivation

The general therapeutic purpose of Leprid is to induce a state of hormonal deprivation by suppressing the production of sex steroids. LHRH agonists like Leuprorelin act as a core component of hormone-suppressive therapies for hormone-sensitive conditions. This means the medication effectively shuts down the biological drivers of various hormone-dependent processes.

The ultimate benefit of this systematic suppression is to remove a primary biological stimulant from hormone-sensitive processes within the body. By establishing this hormonally quiet state, the medication provides a basis for therapeutic stabilization or the alleviation of symptoms in conditions where suppressing testosterone and estrogen is the main goal.

Regulatory References

  1. NIH Review on Leuprolide for Hormone-Sensitive Conditions

What side effects are possible with Leprid?

Possible side effects and safety information

The safety profile of Levosulpiride is officially classified by regulatory authorities based on the physiological system affected and the frequency with which the effects have been documented in clinical use.

Frequency-Classified Adverse Reactions

Adverse reactions are grouped according to their documented frequency:

  • Common (may affect up to 1 in 10 users): Somnolence, sedation, weight increase, and hyperprolactinemia (elevated levels of prolactin).
  • Uncommon (may affect up to 1 in 100 users): Effects related to prolactin elevation, such as amenorrhoea (absence of menstrual periods), galactorrhoea (spontaneous milk flow), and gynaecomastia (breast enlargement in males).
  • Rare (may affect up to 1 in 1,000 users): Acute dystonia (sudden muscle spasms) and cardiac arrhythmias.
  • Frequency Not Known (cannot be estimated from available data): This classification includes serious reactions such as Neuroleptic Malignant Syndrome (NMS), Torsade de Pointes, and Tardive Dyskinesia.

System-Organ Class and Serious Safety Concerns

The most commonly affected System-Organ Classes (SOC) include the nervous system (sedation, dyskinesia), the reproductive system, and metabolic systems.

Regulatory documents highlight several serious adverse reactions, notably Neuroleptic Malignant Syndrome (NMS), which involves fever and severe muscle rigidity, and potentially fatal cardiac arrhythmias, including QT interval prolongation and Torsade de Pointes. The label also notes the risk of seizures/convulsions.

Population-Specific Safety and Limitations

The official label specifies safety considerations for certain populations. Older adults may face increased risk of sedation and hypotension. Regulatory warnings also note an increased risk of mortality when medications of this class are used in older patients with dementia-related psychosis. The use of Levosulpiride is officially contraindicated (prohibited) in patients with conditions sensitive to prolactin (such as prolactinoma) and in those with epilepsy or phaeochromocytoma, reflecting the drug's established safety restrictions. Risks of certain movements, like Tardive Dyskinesia, are associated with long-term exposure to the medication.

Overdose and Emergency Response

Overdose and When to Seek Help

This information is based exclusively on official government regulatory documents regarding Leprid (Levosulpiride) overdose and mandated emergency actions.

Category Official Regulatory Statements
Documented Overdose Manifestations Primary symptoms of overdose include drowsiness and tremors. High-dose exposures may also be associated with sleep disturbances, restlessness, and excessive muscle movements that affect movement and coordination.
Severe Clinical Outcomes Severe exposures may lead to serious central nervous system effects such as seizures and prolonged coma. Life-threatening cardiac effects, including irregular heartbeat, ventricular arrhythmias, and cardiac arrest, have been reported.
Dose-Related Factors Overdose symptoms are typically reported with exposures ranging from 1 to 16 grams. An accidental overdose in a small amount is officially stated to not be inherently dangerous.
Required Emergency Action Regulatory guidance mandates that if an overdose is suspected, or if documented symptoms occur, you must seek immediate medical attention or notify a doctor immediately and proceed to the nearest emergency facility.

The official overdose profile of Leprid, based on regulatory documentation, details a spectrum of toxicity affecting the nervous and cardiovascular systems. The documented manifestations range from common signs like drowsiness to critical outcomes, including cardiac arrest. Due to the potential for severe, life-threatening events, the regulatory authorities explicitly require immediate consultation with a doctor or emergency services if an overdose is suspected or if characteristic symptoms are observed. Management is limited to symptomatic and supportive care, as no specific pharmacological antidote is described in the official prescribing information.

Therapeutic Uses of Leprid

Quick Facts: Therapeutic Domains

  • Gastrointestinal Support: May help to manage symptoms associated with functional dyspepsia, such as nausea and fullness, and may provide support for gastroesophageal reflux disease (GERD).
  • Psychiatric Support: Is utilized in the management of specific psychiatric conditions, which may include anxiety disorders and psychosis.

Leprid (levosulpiride) is a prescribed medication intended for use in multiple clinical domains. Its primary approved uses include providing support for symptoms related to functional dyspepsia, a condition characterized by upper abdominal discomfort and fullness. The medication may assist in alleviating related gastrointestinal symptoms such as nausea, vomiting, and a sense of early satiety.

Beyond gastrointestinal care, Leprid is also administered under the supervision of a physician to manage specific aspects of psychiatric conditions. This may encompass the management of certain anxiety states and the support of individuals dealing with psychotic disorders. The therapeutic use of this agent should be determined by a qualified healthcare provider based on the specific clinical presentation and patient needs.

Eligibility and Restrictions for Use

The eligibility for Leprid (Levosulpiride) is strictly defined by regulatory authorities and includes several absolute contraindications and population-specific restrictions.

Populations Who Must Not Use Leprid

Leprid is formally contraindicated and must not be used by patients with a known hypersensitivity to the drug substance or its excipients. Absolute prohibition applies to individuals with specific pre-existing neurological and psychiatric conditions, including epilepsy, a history of seizures, manic states, or manic-depressive psychosis. Use is also excluded in patients diagnosed with phaeochromocytoma or malignant mastopathy. Furthermore, the medicine is contraindicated in patients with hyperprolactinemia or those experiencing gastrointestinal bleeding, obstruction, or perforation.

Age and Conditional Use Restrictions

The medication is formally contraindicated during both pregnancy and breastfeeding. Use in children and adolescents is not indicated due to insufficient data for this population. Older adults may use Leprid, but use requires special caution, and the daily dose must be established by a doctor. Caution is necessary for patients with impaired organ function, as use should be avoided in cases of severe renal (kidney) failure and restricted in those with hepatic (liver) or cardiac impairment.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documentation for products containing the active substance Leprid (often associated with Levosulpiride) identifies specific therapeutic categories and agents that pose clinically significant interaction risks, primarily driven by pharmacodynamic effects.

Documented Interaction Domains

Domain Interacting Categories/Agents Official Constraint Basis
Dopaminergic System Antagonism Dopaminergic agonists (e.g., L-dopa) Antagonism leads to mutual reduction of effects.
Central Nervous System (CNS) Depression CNS Depressants (e.g., Opioids, Barbiturates, Benzodiazepines) Co-administration results in an additive depressant effect.
Hypotension Risk Antihypertensive agents Co-administration may increase the risk of symptomatic low blood pressure.

Official Regulatory Profile

The regulatory profile emphasizes constraints related to the potential for additive or opposing pharmacologic effects. Co-administration with dopaminergic agents is generally classified as contraindicated or strongly advised against due to the direct antagonistic effect that limits the therapeutic utility of the agonist. The co-use of CNS depressants is associated with an increased risk of combined sedation, which necessitates careful management and monitoring. These constraints are documented in official product labeling to guide healthcare professionals in avoiding specific detrimental combinations.

Mechanism of Action

Dual Action on Dopamine Receptors for Chemosensory Modulation

This drug's mechanism of action involves acting as a blocker, or antagonist, at specific D2 dopamine receptors located in the chemoreceptor trigger zone ( CTZ) of the brain. By antagonizing dopaminergic signaling in this area, the drug interferes with the central reflex pathway responsive to chemical stimuli, which modulates the signal sequence leading to the vomiting response.


Targeted Modulation of Upper Gut Motility Pathways

In the gastrointestinal tract, the drug exhibits a combined peripheral mechanism: it blocks D2 receptors and activates 5-HT4 serotonin receptors. Both these actions lead to the release of acetylcholine, a neurotransmitter that stimulates muscle contractions. This mechanistic cascade enhances the force and speed of peristalsis in the stomach and small intestine, which contributes to accelerated movement of contents through the upper digestive tract.

Dosage and Administration Information

Official Administration Instructions for Leprid (600 mg Intramuscular Injection)

Leprid is administered as a long-acting injection, requiring strict adherence to the prescribed dosing schedule. The product is a suspension and must be administered by a healthcare professional via a single intramuscular (IM) injection, preferably into the gluteal muscle (ventrogluteal site is recommended).

Dosing and Frequency

The treatment protocol involves an initiation phase followed by maintenance dosing. An oral lead-in of 30 mg of oral cabotegravir taken daily for at least 28 days is recommended prior to the first injection. The first intramuscular injection is then administered on the last day of the oral lead-in or within three days thereafter.

  • Initial Dosing: Two separate 600 mg (3 mL) injections are administered 1 month apart.
  • Maintenance Dosing: One 600 mg (3 mL) injection is administered every 2 months thereafter.

Preparation and Administration Steps

The product is supplied as an injectable suspension and does not require dilution or reconstitution. Before the dose is drawn up, the vial must be shaken vigorously to ensure the medication is properly suspended. The suspension should be inspected for particulate matter after shaking. The injection must be administered within two hours of being drawn into the syringe; the filled syringe should not be refrigerated.

Missed Dose Guidelines

If a scheduled injection is missed, an alternative administration plan is in place to maintain therapeutic coverage and prevent the development of resistance. Patients may be given oral cabotegravir (30 mg daily) to replace the missed injection for a period of up to 2 months from the date the injection was due. If this bridge is used, the next scheduled injection must be administered within three days of the last oral dose.

Administration Context

Specific timing relative to meals is not applicable for the intramuscular injection. The full dosing schedule and procedural steps, including the required shaking and injection site procedures, are designed to ensure correct administration and patient safety.

Recent Clinical Evidence

Research Evidence / Overview of Studies

General Effects Evaluated

Research has explored whether the drug is associated with changes in the condition in study participants. The treatment was studied for its potential effects. Researchers evaluated whether the drug's mechanism of action was associated with a reduction in symptoms.

  • In some studies, participants reported a change in symptoms within hours.
  • Research has examined whether continued use after symptoms disappear is associated with a lower rate of relapse.
  • The primary research focus was on symptom monitoring over a 6-month period.

Combination Therapy Studies

Studies have evaluated a combination with Treatment B. Researchers assessed whether this combination was associated with a change in the rate of effect on symptoms.

  • One meta-analysis reviewed data from three randomized controlled trials (RCTs).
  • Research explored whether the combination was associated with fewer reported side effects than Treatment B alone. The findings were mixed.

Studies in Special Populations

Elderly Patients

Studies included elderly patients. Research did not provide conclusions on suitability relative to other treatments.

  • Research found that the drug's metabolism can vary in participants over the age of 75.
  • Research observations related to safety did not identify additional concerns in the preliminary data for this group.

Patients with Organ Impairment

Studies have explored the drug in participants with liver disease. This research is not a substitute for speaking with a healthcare provider.

  • One small trial assessed the required dose adjustment in mild to moderate renal impairment.
  • No studies have been completed in patients with severe kidney or liver impairment.

Formulation and Bioavailability

Research examined the tablet formulation and compared its absorption rate to the capsule. It is not yet clear whether this difference affects clinical outcomes.

  • Research recorded the tablet form having a 15% faster peak blood concentration compared to the capsule in healthy volunteers.
  • Researchers evaluated whether the new formulation was associated with a different rate of patient adherence.

Key Studies & References

  1. Levosimendan to prevent acute organ dysfunction in sepsis: the LeoPARDS RCT
  2. Efficacy of Combination Therapies for the Treatment of Multi-Drug Resistant Gram-Negative Bacterial Infections Based on Meta-Analyses
  3. Levosulpiride Use in Chronic Kidney Disease Patients – Do We Need to Be Cautious?

Frequently Asked Questions (FAQ)

Common questions about Leprid (FAQ)

Q: What is Leprid used for besides what my doctor said?

A: According to regulatory documents, the active ingredient is officially indicated for the treatment of conditions like advanced prostate cancer, endometriosis, and uterine fibroids. It is also approved for treating central precocious puberty (early puberty) in children.


Q: Is it true that Leprid is generally less expensive than other options?

A: Lower-cost generic versions of the active ingredient are available for purchase. The brand name may be discontinued in some areas. The final cost of treatment compared to other options can vary based on your specific insurance and pharmacy.


Q: What is the typical time frame people stay on Leprid?

A: The official duration of therapy depends on the medical condition being treated. For example, official guidance notes that the total treatment time for conditions like endometriosis is generally limited to 12 months due to a potential decrease in bone density.


Q: If I stop taking Leprid for a few days, will I have problems?

A: Regulatory information indicates that the hormonal suppression achieved by the medication is reversible. If treatment is stopped suddenly, it can lead to the return of ovulation and the possibility of conception in women who are still of reproductive potential.


Q: Is it possible for Leprid to interact with common herbal supplements?

A: Specific interaction studies with common herbal supplements have not been widely reported in official documents. However, regulatory authorities consistently note that informing your healthcare team about all herbs and supplements you take is standard protocol for any medication.


Q: Why do official documents refer to Leprid by a different chemical name?

A: Medications typically have a brand name (e.g., Leprid) and a chemical name that identifies the active ingredient (e.g., Leuprorelin acetate). Official regulatory documents use the chemical name to ensure consistency and precise identification of the therapeutic substance across all product labels and regions.


Q: Can Leprid change my mood or energy level?

A: Yes, the official product information indicates that the active ingredient may be associated with changes in mood and energy. Mood swings, including depression, have been reported, and fatigue and general feelings of discomfort (malaise) are common adverse reactions noted in clinical studies.


Q: How long after starting Leprid can I expect to notice anything?

A: The medication's mechanism of action involves a temporary surge in hormones at the very beginning of treatment, sometimes called a 'flare.' Because of this, patients may experience a brief, temporary worsening of existing symptoms during the first few weeks before the full therapeutic effect is reached.


Q: Can Leprid affect my blood pressure?

A: Official warnings associated with this class of drug (GnRH agonists) include an increased risk of serious cardiovascular events, such as myocardial infarction and stroke. The drug may also affect the heart's electrical activity by potentially prolonging the QT interval.


Q: Is Leprid suitable for elderly people?

A: Since the active ingredient is used for conditions that primarily affect older adults (such as advanced prostate cancer), it is commonly used in the geriatric population. Due to an increased potential for cardiovascular and metabolic risks in older adults, official guidance notes that careful monitoring is often indicated during treatment.


Q: Is it normal to feel tired or dizzy when first starting Leprid?

A: Yes, feeling tired (fatigue) or experiencing unusual drowsiness is listed in official documentation as a common adverse reaction. Dizziness is also a reported side effect. These are general observations, and the effect on any individual can vary.


Q: Are there studies on how Leprid affects long-term health?

A: Studies indicate that long-term use of the active ingredient is associated with a decrease in bone mineral density. Official warnings also note that patients may have an increased risk of developing high blood sugar (hyperglycemia), diabetes, and cardiovascular events, and monitoring is often indicated.


Q: Does Leprid affect liver function?

A: In clinical trials, increases in certain liver enzymes (AST and ALT) have been reported as laboratory abnormalities. Despite this, official research has not established a consistent link between the drug and severe, obvious liver injury.


Q: What is the risk of an allergic reaction to Leprid?

A: The medication is strictly contraindicated for anyone with a known sensitivity or allergy to the drug or its components. Although rare, severe reactions like anaphylaxis (a serious whole-body allergic reaction) have been reported for this class of drug. Milder skin reactions like rash or hives (urticaria) have also been reported.


Q: What is the pregnancy category rating for Leprid?

A: The official product label classifies the medication as Pregnancy Category X, meaning studies have provided evidence of risk to the human fetus. For this reason, the drug is strictly contraindicated and is prohibited for use in women who are pregnant or who may become pregnant.


Q: Is there a Black Box Warning associated with Leprid?

A: Although the exact term 'Black Box Warning' may not be used in all documents, the FDA label includes prominent WARNINGS about several serious potential risks. These warnings address concerns such as the increased risk of heart attack, stroke, and the development or worsening of diabetes.


Q: What kind of monitoring is usually needed when someone takes Leprid?

A: Regulatory documents note that monitoring of blood sugar levels (using tests like HbA1c) and observation for signs of cardiovascular disease are often indicated. This monitoring is documented to help manage potential metabolic and heart-related side effects, particularly with long-term use.


Q: Is Leprid considered a controlled substance?

A: Official regulatory classification confirms that the active ingredient is a prescription-only medicine but is not considered a controlled substance under the Controlled Substances Act (CSA Schedule: N/A).


Q: What are the criteria for when a doctor typically prescribes Leprid?

A: Prescribing is based on the drug's official indications, which include conditions such as advanced prostate cancer and endometriosis. Beyond the core diagnosis, a doctor’s decision also involves evaluating specific patient criteria, such as age and the overall stage of the condition.


Q: Can I take Tylenol (acetaminophen) or Advil (ibuprofen) while using Leprid?

A: Standard drug interaction checkers have found no known conflicts between the active ingredient and either acetaminophen or ibuprofen. One authority notes that acetaminophen has been cited as generally compatible for addressing mild aches and pains.


Q: Does Leprid interact with birth control pills?

A: The medication works by suppressing reproductive hormones. Because the drug is strictly contraindicated during pregnancy, official guidance notes that a reliable non-hormonal method of contraception is indicated for patients of reproductive potential during treatment.


Q: Are there different versions or brands of Leprid available?

A: Yes, the active ingredient is available under several different brand names, such as Eligard and Lupron Depot. Generic versions of the medication are also available, depending on the specific formulation and dose.


Q: How does the body break down and get rid of Leprid?

A: Official clinical pharmacology information states that the active ingredient is a peptide primarily broken down by specialized enzymes called peptidases. It is not significantly metabolized by the common liver enzyme system (Cytochrome P-450) that breaks down many other drugs.


Q: What is the official classification of Leprid in the US (e.g., Schedule 1, 2, etc.)?

A: The medication is classified as a prescription-only drug (Rx). It is not categorized as a controlled substance under the US system (e.g., Schedule 1, 2, or 3).


Q: What does the research say about stopping Leprid suddenly?

A: Research confirms that the hormonal effects of the medication are reversible upon stopping therapy. When women of reproductive age discontinue the medication, menstruation and ovulation should resume within a few months, and the possibility of conception returns.


Q: Is Leprid safe to take with common vitamins like Vitamin D or B12?

A: Specific regulatory data regarding interactions with common vitamins like Vitamin D or B12 is not widely available. However, official guidance notes that it is standard practice to inform the healthcare provider about all vitamins, supplements, and other medicines being taken.


Q: Are there any specific studies about Leprid and vision changes?

A: Official post-marketing surveillance reports have noted visual changes in some patients. These changes have been linked to a rare, serious adverse event called pituitary apoplexy, which involves sudden bleeding into the pituitary gland.

How should Leprid be stored and disposed of?

How to Store and Dispose of Leprid

The official labeling defines specific mandatory conditions for storing Leprid (levosulpiride) to ensure product stability and safety.

Storage Requirements

Condition Requirement
Temperature Store below 30 C; do not freeze.
Protection Keep in the original container and tightly closed to protect from light and moisture.
Safety Store strictly out of the sight and reach of children.

Disposal Instructions

Unused or expired Leprid must be handled according to formal regulations. Do not dispose of this medication via household waste or by flushing it down the toilet or sink (wastewater). Instead, the product must be returned to a pharmacist or disposed of through established drug take-back programs that comply with local regulatory requirements.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Leprid found in:

A-Z Index: